Content |
Recently, Hyundai Pharm. signed a contract with ForHumanTech to develop new drug candidate, HFT-401, for Rheumatoid Arthritis.
HFT-40 is a synthetic component composed of an existing drug, MTX (methotrexate), to treat Reumatoid Arthritis and PTD (Protein Transduction Domain) to improve permeability on the skin. |